COVID-19 Antibody Cocktail Yields Encouraging Study Results

Regeneron Pharmaceuticals announced on December 29, 2020, the initial data for the therapy in hospitalized COVID-19 patients requiring low-flow oxygen as encouraging. The results are from the ongoing Phase 1/2/3 clinical trial for its antibody cocktail.

According to Regeneron's press statement, the study's results have passed the futility analysis with seronegative patients treated having a lower risk of death or receiving mechanical. And in seronegative patients, the antibody cocktail reduced the time-weighted average daily viral load.

David Weinreich, M.D., SVP and Head of Global Clinical Development at Regeneron, commented, "Hospitalizations due to COVID-19 are increasing around the globe and have devastating consequences for these patients, their families and those who care for them, highlighting the need for effective therapeutics. We plan to share these most recent data with regulatory authorities."

In November 2020, the Regeneron antibody cocktail was granted an Emergency Use Authorization by the U.S. FDA in high-risk patients who have confirmed COVID-19 but are not currently hospitalized.